Evidence Snapshot

Delta-type opioid receptor

CHEMBL236 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T03:20:34Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 12:20 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL236

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Delta-type opioid receptor as ChEMBL target CHEMBL236, mapped to UniProt P41143. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Delta-type opioid receptor

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL236

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P41143

Delta-type opioid receptor

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Delta-type opioid receptor matters

As of 2026-09-13

Delta-type opioid receptor is reviewed as Delta-type opioid receptor (UniProt P41143); Delta-type opioid receptor shows approved-linked disease relevance led by alcohol dependence. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 79 approved drugs, 9545 compounds, and 1631 assays, with lead potency reaching pChEMBL 11.0.

Protein context

Delta-type opioid receptor

Delta-type opioid receptor Sequence length is 372 aa.

Review this target as Delta-type opioid receptor, mapped to UniProt P41143. Sequence length is 372 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P41143 Protein

Disease context

alcohol dependence

Delta-type opioid receptor shows approved-linked disease relevance led by alcohol dependence. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include NALMEFENE HYDROCHLORIDE DIHYDRATE.

Start review with alcohol dependence because it currently carries approved-linked support. Linked drugs include NALMEFENE HYDROCHLORIDE DIHYDRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 1 linked drug

Activity base

Portfolio and assay base

ChEMBL currently tracks 79 approved drugs, 9545 compounds, and 1631 assays for this target. The dominant activity type is KI. CHEMBL67192 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL67192 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine

79 approved pChEMBL 11.0

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Delta-type opioid receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P41143, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why alcohol dependence is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

9545

Total Compounds

1631

Total Assays

Approved Drugs

IC50: 2492.0, KI: 6349.0, EC50: 2045.0, KD: 48.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL67192	11.0	Ki	—
No preferred name CHEMBL132420	10.9	Ki	—
No preferred name CHEMBL100940	10.9	Ki	—
No preferred name CHEMBL132897	10.8	Ki	—
No preferred name CHEMBL2151735	10.8	EC50	—

Approved Drugs

Structure	Compound	First Approval
	SAMIDORPHAN CHEMBL426084	2021
	NALDEMEDINE CHEMBL2105755	2017
	NALFURAFINE HYDROCHLORIDE CHEMBL490665	2009
	NALFURAFINE CHEMBL267495	2009
	METHYLNALTREXONE CHEMBL1186579	2008
	METHYLNALTREXONE BROMIDE CHEMBL1201770	2008
	ALVIMOPAN CHEMBL270190	2008
	NALMEFENE CHEMBL982	1995
	TRAMADOL CHEMBL1237044	1995
	LEVORPHANOL CHEMBL592	1991
	NALTREXONE CHEMBL19019	1984
	MORPHINE CHEMBL70	1984
	HYDROMORPHONE CHEMBL398707	1984
	ECONAZOLE CHEMBL808	1982
	BUPRENORPHINE CHEMBL511142	1981
	BUPRENORPHINE HYDROCHLORIDE CHEMBL2368861	1981
	NALBUPHINE CHEMBL895	1979
	BUTORPHANOL CHEMBL33986	1978
	LOPERAMIDE HYDROCHLORIDE CHEMBL1707	1976
	LOPERAMIDE CHEMBL841	1976
	DIETHYLSTILBESTROL CHEMBL411	1973
	NALOXONE CHEMBL80	1971
	FENTANYL CHEMBL596	1968
	PENTAZOCINE CHEMBL100116	1967
	OXYMORPHONE CHEMBL963	1959

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T03:20:34Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 12:20 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL236